P Phowthongkum1,2, C Ittiwut3, V Shotelersuk4. 1. Division of Medical Genetics and Genomics, Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand. Prasit.ph@chula.ac.th. 2. Medical Genetics Center, King Chulalongkorn Memorial Hospital, The Thai Red Cross Society, Bangkok, Thailand. Prasit.ph@chula.ac.th. 3. Center of Excellence for Medical Genetics, Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand. 4. Excellence Center for Medical Genetics, King Chulalongkorn Memorial Hospital, The Thai Red Cross Society, Bangkok, Thailand.
Abstract
BACKGROUND: Carnitine palmitoyltransferase II (CPTII) deficiency is a mitochondrial fatty acid oxidation disorder that can present antenatally as congenital brain malformations, or postnatally with lethal neonatal, severe infantile, or the most common adult myopathic forms. No case of severe hyperammonemia without liver dysfunction has been reported. CASE PRESENTATION: We described a 23-year-old man who presented to the emergency department with seizures and was found to have markedly elevation of serum ammonia. Continuous renal replacement therapy was initiated with successfully decreased ammonia to a safety level. He had a prolonged history of epilepsies and encephalopathic attacks that was associated with high ammonia level. Molecular diagnosis revealed a homozygous mutation in CPTII. The plasma acylcarnitine profile was consistent with the diagnosis. Failure to produce acetyl-CoA, the precursor of urea cycle from fatty acid in prolonged fasting state in Ramadan month, worsening mitochondrial functions from circulating long chain fatty acid and valproate toxicities were believed to contribute to this critical metabolic decompensation. CONCLUSION: Fatty acid oxidation disorders should be considered in the differential diagnosis of hyperammonemia even without liver dysfunction. To our knowledge, this is the first case of CPTII deficiency presented with severe hyperammonemic encephalopathy required dialysis after prolonged religious related fasting.
BACKGROUND:Carnitine palmitoyltransferase II (CPTII) deficiency is a mitochondrial fatty acidoxidation disorder that can present antenatally as congenital brain malformations, or postnatally with lethal neonatal, severe infantile, or the most common adult myopathic forms. No case of severe hyperammonemia without liver dysfunction has been reported. CASE PRESENTATION: We described a 23-year-old man who presented to the emergency department with seizures and was found to have markedly elevation of serum ammonia. Continuous renal replacement therapy was initiated with successfully decreased ammonia to a safety level. He had a prolonged history of epilepsies and encephalopathic attacks that was associated with high ammonia level. Molecular diagnosis revealed a homozygous mutation in CPTII. The plasma acylcarnitine profile was consistent with the diagnosis. Failure to produce acetyl-CoA, the precursor of urea cycle from fatty acid in prolonged fasting state in Ramadan month, worsening mitochondrial functions from circulating long chain fatty acid and valproatetoxicities were believed to contribute to this critical metabolic decompensation. CONCLUSION:Fatty acidoxidation disorders should be considered in the differential diagnosis of hyperammonemia even without liver dysfunction. To our knowledge, this is the first case of CPTII deficiency presented with severe hyperammonemic encephalopathy required dialysis after prolonged religious related fasting.
Authors: F Boemer; M Deberg; R Schoos; J-H Caberg; S Gaillez; C Dugauquier; K Delbecque; A François; P Maton; N Demonceau; G Senterre; S Ferdinandusse; F-G Debray Journal: Clin Genet Date: 2015-05-05 Impact factor: 4.438
Authors: M Fanin; A Anichini; D Cassandrini; C Fiorillo; S Scapolan; C Minetti; M Cassanello; M A Donati; G Siciliano; A D'Amico; F Lilliu; C Bruno; C Angelini Journal: Clin Genet Date: 2011-10-12 Impact factor: 4.438
Authors: K Wataya; J Akanuma; P Cavadini; Y Aoki; S Kure; F Invernizzi; I Yoshida; J Kira; F Taroni; Y Matsubara; K Narisawa Journal: Hum Mutat Date: 1998 Impact factor: 4.878